About: Cyclerion Therapeutics, Inc., a biopharmaceutical company, engages in the development of treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. The company is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $3.36 (-20.94%)
Status: deslistada — removed_from_provider. Este ativo não é mais negociado; são exibidos dados históricos.
CYCN NASDAQ Cyclerion Therapeutics Inc
Cyclerion Therapeutics Inc share price
Atividade de preço de CYCN
Último preço
Variação (24h)
USD
Volume
-
Volume (média 4 sem.)
-
Fechamento anterior
N/D
Último negócio
CYCN price performance
quote.marketSignals